{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fmy-take-easl-2022-N3gFtU3U","width":444,"version":"1.0","type":"rich","title":"Advancements in Viral Hepatitis From EASL 2022","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/1bcd934c-4006-45bd-a82e-f6b04c461281/pod541-easl-cf-podcast-ct.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/b0215eca-f704-414e-ba7f-da2ac1c93ab1\" height=\"200\" width=\"100%\" title=\"Advancements in Viral Hepatitis From EASL 2022\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to expert insights from Nancy Reau, MD, on updates and new viral hepatitis data from EASL 2022, including HBV novel therapeutics in development, therapeutic vaccination for HBV, emerging treatments for HDV, HCV care cascade, and the need for HCC monitoring post HCV cure."}